We undertook a prospective cogitation of bronchoprovocation challenge (BPC) to expect at issues of safety and reversibility of bronchospasm and symptoms induced by means of BPC.

We undertook a prospective cogitation of bronchoprovocation challenge (BPC) to expect at issues of safety and reversibility of bronchospasm and symptoms induced by means of BPC. Over a 14-month interval, we documented 62 consecutive cases of bronchial hyperresponsiveness. During BPC there was a statistically significant however clinically modest increase in one as well as the other cough and dyspnea. Both bronchospasm and symptoms were readily revers with a simple protocol of inhaled albuterol using a metered-dose inhaler with a spacer. Routine protocol was effective in each case; there was never a ne for individualized physician intervention. Our prospective data document the safety of BPC; we could find no reason to what end BPC would need to be confined to the hospital. We decide that BPC is a valuable clinical example which merits wider dissemination and use.

BHR = bronchial hyperresponsiveness; BHR + = demeanor of BHR; BHR - = no BHR; BPC = bronchoprovocation challenge; PC20 = provocative concentration causing 20 percent small quantity in [FEV.sub.1]

Bronchoprovocation challenge (BPC) is an important tool for the diagnosis of asthma: BPC demonstrating bronchial hyperresponsiveness (BHR) can help to confirm a diagnosis of asthma; BPC has allowed us to understand and diagnose cough-variant asthma and to evaluate the part of BHR in chronic cough; and BPC plays an important part in the evaluation of dyspnea.[1-5] The absence of BHR can also be actual useful clinically, as it makes a diagnosis of asthma self-same unlikely, even in the patient with classic asthma-like symptoms.[1] Despite its documented clinical utility,[1-4], BPC is not used as widely as it could be, leaving many clinicians with the task of diagnosing asthma in succession clinical grounds alone.[5] One reason for the underutilization of BPC has been a fear that the touchstone is unsafe.[6] In more than 10 years of clinical experience with BPC involving several thousand trials we have come to believe that BPC is actually actual safe and that concerns about safety are unfounded[1] In the literature, we have ground reviews describing large numbers of challenges without adverse weights but have not found formal prospective documentation of this belief.[1,7] We therefore wished to establish a formal protocol and to document prospectively for what reason and in what time span the clinical and spirometric weights of methacholine can be reversed

Materials and Methods

each BPC completed by our laboratory from June 8 1990 until Aug 27 1991 was included in the inquiry Data collection began with a two-page questionnaire filled disclosed by the patient describing his or her symptoms or disease. After the patient had filled revealed the questionnaire, the technician performing the BPC recorded demographics for each patient.

principally spirometric values were obtained with a Sensormedics 2100 spirometer. A small in number studies were performed on Sensormedics 2130 Sensormedics 2200 and Sensormedics 6200 spirometers. Computer software was uniform for all plans The test solutions were aerosolized using a nebulizer (DeVilbiss 646) with close tightlyed air at 8 L/min. The measured output of the ten nebulizers in our laboratory range from 026 to 028 ml/min, with a mean of 027 ml/ min.

The methacholine BPC was performed according to the tidal compass method of Hargreave et al.[8-10] After the inhalation of plain physiologic saline solution (NaCl) to establish the baseline [FEVsub1] for the BPC dilutions of methacholine in NaCl were delivered in sequentially higher concentrations (0125 ing/ml, 025 mg/ml 05 mg/ml 1 mg/ml 2 mg/ml 4 mg/ml and 8 mg(ml) Each concentration was inhaled for 2 min, with spirometry obtained 1 min after the extremity of that dose. The BPC was terminated when a pendant of at least 20 percent in [FEVsub1] had occurr or after the highest concentration had been administered.

If methacholine did induce a ear-ring in [FEV.sub.1], of 20 percent or more, the extrapolated concentration at which a 20 percent pendant in [FEV.sub.1], had occurred was calculated and period of timeed the PC20. Patients with a PC20 of 8 mg/ml or les were considered to have increased bronchial hyperresponsiveness (BHR +) Patients with les than a 20 percent globule in [FEV.sub.1], after methacholine at 8 mg/ml were considered not to have clinically relevant bronchial hyperresponsiveness (BHR -)

Our protocol is that all patients proven to be BHR + are immediately given 2 inhalations of albuterol, 1 min apart, using a metered-dose inhaler with a spacer (Aerochamber). Spirometry is performed 5 min after the other inhalation. If the [FEV.sub.1], has not reverted to within 10 percent of baseline by the agency of that time, a single third inhalation of albuterol is administered. No further albuterol is administered; spirometry is performed each 5 min until the [FEVsub1] has reverted to within 10 percent of the baseline before methacholine, at which time the [FEVsub1] is holded "acceptable" for discharge from the laboratory if after 30 min the [FEVsub1] is not within 10 percent of the baseline before BPC the pulmonologist covering the pulmonary function laboratory is to be called for further instructions.

...